Patient-derived orthotopic xenograft models of sarcoma

Author:

Igarashi, Kentaro

Kawaguchi, Kei

Murakami, Takashi

Miyake, Kentaro

Kiyuna, Tasuku

Miyake, Masuyo

Hiroshima, Yukihiko

Higuchi, Takashi

Oshiro, Hiromichi

Nelson, Scott D

Dry, Sarah M

Li, Yunfeng

Yamamoto, Norio

Hayashi, Katsuhiro

Kimura, Hiroaki

Miwa, Shinji

Singh,Shree Ram

Tsuchiya, Hiroyuki

Hoffman, Robert M
Author Address

AntiCancer, Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan., AntiCancer, Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA., Department of Pathology, University of California, Los Angeles, CA, USA., Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov., Department of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan. Electronic address: tsuchi@med.kanazawa-u.ac.jp., AntiCancer, Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.,

Abstract:

Sarcoma is a rare and recalcitrant malignancy. Although immune and novel targeted therapies have been tested on many cancer types, few sarcoma patients have had durable responses with such therapy. Doxorubicin and cisplatinum are still first line chemotherapy after four decades. Our laboratory has established the patient-derived orthotopic xenograft (PDOX) model using surgical orthotopic implantation (SOI). Many promising results have been obtained using the sarcoma PDOX model for identifying effective approved drugs and experimental therapeutics, as well as combinations of them for individual patients. In this review, we present our laboratory's experience with PDOX models of sarcoma, and the ability of the PDOX models to identify effective approved agents-as well as experimental-therapeutics. Copyright © 2019. Published by Elsevier B.V.

See More

Author Address